Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis

NCT01559038 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 483

Last updated 2020-11-19

No results posted yet for this study

Summary

The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).

Conditions

Sponsors & Collaborators

  • Cato Research

    collaborator INDUSTRY
  • JSS Medical Research Inc.

    collaborator INDUSTRY
  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-16
Primary Completion
2019-11-19
Completion
2019-11-19

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01559038 on ClinicalTrials.gov